Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Return on Sales (2017 - 2025)

Crinetics Pharmaceuticals has reported Return on Sales over the past 9 years, most recently at 0.2% for Q4 2025.

  • For Q4 2025, Return on Sales rose 267.0% year-over-year to 0.2%; the TTM value through Dec 2025 reached 0.6%, up 226.0%, while the annual FY2025 figure was 0.6%, 226.0% up from the prior year.
  • Return on Sales for Q4 2025 was 0.2% at Crinetics Pharmaceuticals, up from 9.1% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.11% in Q1 2022 and troughed at 9.1% in Q3 2025.
  • A 5-year average of 1.6% and a median of 0.96% in 2022 define the central range for Return on Sales.
  • Biggest five-year swings in Return on Sales: soared 1013bps in 2021 and later crashed -647bps in 2025.
  • Year by year, Return on Sales stood at 0.29% in 2021, then plummeted by -125bps to 0.64% in 2022, then rose by 19bps to 0.52% in 2023, then crashed by -450bps to 2.87% in 2024, then skyrocketed by 93bps to 0.2% in 2025.
  • Business Quant data shows Return on Sales for CRNX at 0.2% in Q4 2025, 9.1% in Q3 2025, and 1.12% in Q2 2025.